Bank of New York Mellon
CHRS icon

Bank of New York Mellon’s Coherus Oncology CHRS Stock Holding History

Bank of New York Mellon’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
319,687
+34,654
+12% +$56.6K ﹤0.01% 3803
2026
Q1 		$482K Sell
285,033
-5,830
-2% -$10.4K ﹤0.01% 3628
2025
Q4 		$413K Sell
290,863
-85,822
-23% -$125K ﹤0.01% 3708
2025
Q3 		$618K Sell
376,685
-13,628
-3% -$15.2K ﹤0.01% 3477
2025
Q2 		$285K Buy
390,313
+1,192
+0.3% +$1.03K ﹤0.01% 3829
2025
Q1 		$314K Sell
389,121
-1,881
-0.5% -$2.17K ﹤0.01% 3681
2024
Q4 		$540K Buy
391,002
+82,222
+27% +$92.2K ﹤0.01% 3483
2024
Q3 		$321K Sell
308,780
-80,445
-21% -$110K ﹤0.01% 3729
2024
Q2 		$673K Buy
389,225
+80,222
+26% +$161K ﹤0.01% 3408
2024
Q1 		$739K Sell
309,003
-45,268
-13% -$111K ﹤0.01% 3312
2023
Q4 		$1.18M Sell
354,271
-41,256
-10% -$111K ﹤0.01% 3106
2023
Q3 		$1.48M Sell
395,527
-194,521
-33% -$898K ﹤0.01% 2967
2023
Q2 		$2.52M Buy
590,048
+29,148
+5% +$172K ﹤0.01% 2708
2023
Q1 		$3.84M Sell
560,900
-18,508
-3% -$144K ﹤0.01% 2443
2022
Q4 		$4.59M Sell
579,408
-44,483
-7% -$342K ﹤0.01% 2388
2022
Q3 		$6M Buy
623,891
+44,580
+8% +$451K ﹤0.01% 2193
2022
Q2 		$4.19M Sell
579,311
-17,734
-3% -$154K ﹤0.01% 2401
2022
Q1 		$7.71M Sell
597,045
-112,239
-16% -$1.43M ﹤0.01% 2217
2021
Q4 		$11.3M Sell
709,284
-105,087
-13% -$1.84M ﹤0.01% 2036
2021
Q3 		$13.1M Buy
814,371
+23,272
+3% +$341K ﹤0.01% 1972
2021
Q2 		$10.9M Sell
791,099
-38,526
-5% -$546K ﹤0.01% 2088
2021
Q1 		$12.1M Buy
829,625
+5,389
+0.7% +$91.5K ﹤0.01% 1986
2020
Q4 		$14.3M Buy
824,236
+114,070
+16% +$2.03M ﹤0.01% 1812
2020
Q3 		$13M Buy
710,166
+5,010
+0.7% +$93.2K ﹤0.01% 1707
2020
Q2 		$12.6M Buy
705,156
+428,210
+155% +$7.25M ﹤0.01% 1696
2020
Q1 		$4.49M Sell
276,946
-1,425
-0.5% -$26.3K ﹤0.01% 2124
2019
Q4 		$5.01M Buy
278,371
+5,632
+2% +$104K ﹤0.01% 2344
2019
Q3 		$5.53M Sell
272,739
-42,815
-14% -$855K ﹤0.01% 2234
2019
Q2 		$6.97M Buy
315,554
+90,856
+40% +$1.58M ﹤0.01% 2180
2019
Q1 		$3.06M Buy
224,698
+2,156
+1% +$28.8K ﹤0.01% 2568
2018
Q4 		$2.01M Buy
222,542
+8,766
+4% +$101K ﹤0.01% 2722
2018
Q3 		$3.53M Buy
213,776
+27,489
+15% +$487K ﹤0.01% 2559
2018
Q2 		$2.61M Buy
186,287
+9,299
+5% +$133K ﹤0.01% 2711
2018
Q1 		$1.96M Buy
176,988
+11,065
+7% +$121K ﹤0.01% 2822
2017
Q4 		$1.46M Sell
165,923
-7,618
-4% -$81.6K ﹤0.01% 3026
2017
Q3 		$2.32M Buy
173,541
+3,701
+2% +$49K ﹤0.01% 2759
2017
Q2 		$2.44M Buy
169,840
+4,700
+3% +$90.4K ﹤0.01% 2735
2017
Q1 		$3.49M Buy
165,140
+25,108
+18% +$618K ﹤0.01% 2517
2016
Q4 		$3.94M Buy
140,032
+5,905
+4% +$165K ﹤0.01% 2456
2016
Q3 		$3.59M Sell
134,127
-3,730
-3% -$102K ﹤0.01% 2410
2016
Q2 		$2.33M Buy
137,857
+36,650
+36% +$688K ﹤0.01% 2617
2016
Q1 		$2.15M Buy
101,207
+18,272
+22% +$299K ﹤0.01% 2615
2015
Q4 		$1.9M Sell
82,935
-1,547
-2% -$39.8K ﹤0.01% 2741
2015
Q3 		$1.69M Sell
84,482
-10,427
-11% -$317K ﹤0.01% 2841
2015
Q2 		$2.74M Buy
94,909
+38,084
+67% +$963K ﹤0.01% 2712
2015
Q1 		$1.74M Buy
56,825
+40,073
+239% +$1.04M ﹤0.01% 2967
2014
Q4 		$273K Buy
+16,752
New +$236K ﹤0.01% 3809

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TWP
Tyche Wealth Partners Plano, Texas $712M AUM 29.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of New York Mellon's CHRS Position: Q2 2026 in Review

Bank of New York Mellon increased its Coherus Oncology (CHRS) stake by 12% in Q2 2026, buying an estimated $56.6K and bringing the position to 319,687 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #3803.

Bank of New York Mellon first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $14.3M in Q4 2020. 60 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Bank of New York Mellon held 319,687 shares of Coherus Oncology worth $448K as of Q2 2026.
  • Bank of New York Mellon bought 34,654 Coherus Oncology shares in Q2 2026, an estimated $56.6K.
  • Coherus Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3803 holding.
  • Bank of New York Mellon first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
  • Bank of New York Mellon's Coherus Oncology position peaked at $14.3M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.